ArticleJournal of thoracic disease2026
Technical nuances and early outcomes of uniportal subxiphoid video-assisted thoracoscopic surgery (VATS) for anterior mediastinal tumor resection without artificial pneumothorax: a retrospective analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of anterior mediastinal masses primarily utilizes video-assisted thoracoscopic surgery (VATS) through the lateral thoracic approach. This study introduced a subxiphoid uniportal VATS for anterior mediastinal tumor resection without artificial pneumothorax and analysed its technical nuances and early outcomes. Methods: A retrospective analysis was conducted on the clinical data of 52 patients with anterior mediastinal tumors admitted to Department of Thoracic Tumor Surgery, West District of the First Affiliated Hospital of University of Science and Technology of China, from January 2023 to August 2025. The cohort included 17 males and 35 females, with ages ranging from 16 to 79 years (mean, 53.15±13.88 years). The maximum tumor diameter ranged from 1.3 to 8.2 cm (mean, 3.41±1.76 cm). All patients underwent uniportal VATS tumor resection via a subxiphoid approach without carbon dioxide (CO2) artificial pneumothorax. Results: All 52 patients successfully completed the surgery without intraoperative hemorrhage, conversion to open thoracotomy, or phrenic nerve injury. There were no severe perioperative complications, such as massive intrathoracic bleeding, secondary surgery, or mortality. The operation time ranged from 30 to 201 minutes (mean, 101.19±42.45 minutes). The intraoperative blood loss was 10 to 100 mL (mean, 32.88±22.65 mL). Postoperative pleural drainage volume was 50 to 1,175 mL (mean, 357.73±246.55 mL), with a chest tube duration of 3 to 8 days (mean, 4.42±1.26 days). The postoperative hospital stay was 3 to 9 days (mean, 5.65±1.36 days). Conclusions: For anterior mediastinal tumors with an intact capsule, no obvious invasion, and a maximum tumor diameter ≤5 cm, uniportal VATS via the subxiphoid approach without artificial pneumothorax is technically safe and feasible, with minimal surgical trauma, mild postoperative pain, and satisfactory short-term outcomes, and is therefore worthy of clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.